迷幻药市场规模、份额和成长分析（按来源、类型、药物、用途、给药途径、最终用户、通路和地区划分）—2026-2033年产业预测

预计到 2024 年，迷幻药市场规模将达到 30.667 亿美元，到 2025 年将成长至 34.7457 亿美元，到 2033 年将成长至 94.3498 亿美元，在预测期（2026-2033 年）内复合成长率 13.3%。

受人们对精神健康治疗日益增长的兴趣以及对压力、焦虑和忧郁症等问题解决方案的迫切需求的推动，迷幻药市场正经历着显着增长。这些物质为精神疾病的管理提供了不同的替代机制，但疗效不一。政府和精神健康组织的倡议正在推动这一增长，而情绪障碍（尤其是在年轻人中）的增加也推动了对创新疗法的需求。儘管副作用和监管障碍等挑战依然存在，但迷幻药在治疗领域的日益普及预示着该行业的良好前景。对这些药物的持续投资和研发表明其前景光明，随着精神健康护理的不断发展，迷幻药市场已成为相关人员需要重点关注的领域。

迷幻药市场驱动因素

迷幻药物的受欢迎程度正在迅速飙升，它们被视为治疗和康復心理健康问题的潜在方案。迷幻药物缓解忧郁症症状的能力吸引了许多研究人员和科学家的关注，他们正积极探索其治疗价值。该领域的持续创新和研究提高了人们对迷幻药物的接受度和认知度，促使其广泛应用。这种日益增长的兴趣和在各个应用领域取得的成功，显着推动了各地对迷幻药物需求的成长，凸显了这些药物成为市场主要驱动力的潜力。

对迷幻药市场的限制

迷幻药市场的成长可能受到这些物质高昂成本的阻碍。此外，严格的监管和合规要求也构成进一步的障碍，可能影响市场扩张。这些财务和监管方面的挑战可能会造成迷幻药普及和上市速度放缓的环境，最终抑制整体市场成长。随着业界努力应对这些复杂的挑战，高成本和严格的法律体制可能会限制这些产品在医疗保健和治疗领域中得到更广泛的接受和应用。

迷幻药市场的趋势

迷幻药市场的一个显着趋势是医院药局领域的成长，这主要得益于大众对心理健康问题和迷幻药治疗潜力的日益关注。随着越来越多的人寻求专业协助，对这些需要医疗专业人员处方才能处方笺的药物的需求也随之激增。这种转变不仅强化了医院药局作为通路的作用，也促使它们更参与某些疾病的治疗管理。因此，迷幻药与医疗保健系统的日益融合，预示着治疗模式和药房运作正在发生重大变革。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管环境
• 专利分析
• 案例研究
• 客户和购买标准分析

全球迷幻药市场规模（按来源和复合年增长率划分）（2026-2033 年）

• 合成
• 自然的

全球迷幻药市场规模（按类型和复合年增长率划分）（2026-2033 年）

• 共济剂
• 分离性药物
• 其他的

全球迷幻药市场规模（按药物类型和复合年增长率划分）（2026-2033 年）

• γ-羟基丁酸（GHB）
• 氯胺酮
• 裸盖菇素
• 麦角酸二乙酰胺（LSD）
• 3,4-亚甲基安非他命（MDMA）
• 其他的

全球迷幻药市场规模（按应用及复合年增长率划分）（2026-2033 年）

• 嗜睡症
• 难治性忧郁症
• 重度忧郁症
• 阿片类成瘾
• 创伤后压力症候群（PTSD）
• 其他的

全球迷幻药市场规模（依给药途径及复合年增长率划分）（2026-2033 年）

• 口服
• 吸入
• 注射

全球迷幻药市场规模（依最终用户划分）及复合年增长率（2026-2033 年）

• 医院
• 专科诊所
• 居家医疗
• 其他的

全球迷幻药市场规模（依分销管道划分）及复合年增长率（2026-2033 年）

• 医院药房
• 零售药房
• 网路药房

全球迷幻药市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2021-2023年营收年比比较

主要企业简介

• Pfizer Inc.（USA）
• Johnson & Johnson（USA）
• AbbVie Inc.（USA）
• Jazz Pharmaceuticals（Ireland）
• Compass Pathways（UK）
• MindMed（Canada）
• Atai Life Sciences（Germany）
• Cybin Corp.（Canada）
• Field Trip Health（Canada）
• GH Research（Ireland）
• Beckley Psytech（UK）
• Seelos Therapeutics（USA）
• Numinus Wellness Inc.（Canada）
• Delix Therapeutics（USA）
• Mydecine Innovations Group（Canada）
• Revive Therapeutics Ltd.（Canada）
• Entheon Biomedical（Canada）
• Mind Cure Health Inc.（Canada）
• PsyBio Therapeutics（USA）
• Tryp Therapeutics（USA）

结论与建议

Psychedelic Drugs Market size was valued at USD 3066.7 Million in 2024 and is poised to grow from USD 3474.57 Million in 2025 to USD 9434.98 Million by 2033, growing at a CAGR of 13.3% during the forecast period (2026-2033).

The market for psychedelic drugs is experiencing significant growth driven by heightened awareness of mental health treatment and the urgent need to address issues like stress, anxiety, and depression. These substances offer alternative mechanisms for managing mental conditions, with varying degrees of effectiveness. Initiatives from governments and mental health organizations are fostering this growth, as increased prevalence of mood disorders, notably among youth, creates a greater demand for innovative treatments. Although challenges remain, such as side effects and regulatory hurdles, the expanding acceptance of psychedelics in therapeutic settings bodes well for the industry. Continued investment and research into these drugs suggest a promising future, making the psychedelic drug market a key area for stakeholders to monitor amid ongoing developments in mental health care.

Top-down and bottom-up approaches were used to estimate and validate the size of the Psychedelic Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Psychedelic Drugs Market Segments Analysis

Global Psychedelic Drugs Market is segmented by source, type, drug, application, route of administration, end-user, distribution channel and region. Based on source, the market is segmented into synthetic and natural. Based on type, the market is segmented into empathogens, dissociatives and others. Based on drug, the market is segmented into gamma-hydroxybutyric acid (GHB), ketamine, psilocybin, lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA) and others. Based on application, the market is segmented into narcolepsy, treatment-resistant depression, major depressive disorder, opiate addiction, post-traumatic stress disorder (PTSD) and others. Based on route of administration, the market is segmented into oral, inhalation and injectable. Based on end-user, the market is segmented into hospitals, specialty clinics, homecare and others. Based on distribution channel, the market is segmented into hospital pharmacy, retail pharmacy and online pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Psychedelic Drugs Market

The popularity of psychedelic drugs has surged as they emerge as potential solutions for mental health treatment and healing. Their ability to alleviate conditions like depression has captured the interest of researchers and scientists who are exploring their therapeutic value. With ongoing innovation and research in this field, there is a growing acceptance and recognition of psychedelic medications, driving their use and adoption. This escalating interest and success observed in various applications have significantly contributed to the increasing demand for psychedelic substances across various regions, highlighting the potential of these drugs as major drivers in the market.

Restraints in the Psychedelic Drugs Market

The growth of the psychedelic drugs market is likely to be hindered by the substantial expenses associated with these substances. Additionally, the presence of rigid regulations and compliance requirements presents further obstacles that may affect market expansion. These financial and regulatory challenges create an environment that could slow the adoption and accessibility of psychedelic drugs, ultimately restraining overall market growth. As the industry navigates these complexities, the combination of high costs and stringent legislative frameworks could limit the potential for wider acceptance and integration of these products in healthcare and therapeutic settings.

Market Trends of the Psychedelic Drugs Market

The psychedelic drugs market is witnessing a notable trend towards the growth of the hospital pharmacy segment, fueled by heightened public awareness surrounding mental health issues and the therapeutic potential of psychedelics. As more individuals seek professional help, the demand for these substances, which necessitate prescriptions from medical practitioners, is surging. This shift is not only enhancing the role of hospital pharmacies as distribution channels but also catalyzing their involvement in the management of specific medical conditions. Consequently, this increasing integration of psychedelics into healthcare frameworks underscores a significant transformation in treatment paradigms and pharmacy operations.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Patent Analysis
• Case Studies
• Customer & Buying Criteria Analysis

Global Psychedelic Drugs Market Size by Source & CAGR (2026-2033)

• Market Overview
• Synthetic
• Natural

Global Psychedelic Drugs Market Size by Type & CAGR (2026-2033)

• Market Overview
• Empathogens
• Dissociatives
• Others

Global Psychedelic Drugs Market Size by Drug & CAGR (2026-2033)

• Market Overview
• Gamma-Hydroxybutyric Acid (GHB)
• Ketamine
• Psilocybin
• Lysergic Acid Diethylamide (LSD)
• 3,4-Methylenedioxymethamphetamine (MDMA)
• Others

Global Psychedelic Drugs Market Size by Application & CAGR (2026-2033)

• Market Overview
• Narcolepsy
• Treatment-Resistant Depression
• Major Depressive Disorder
• Opiate Addiction
• Post-Traumatic Stress Disorder (PTSD)
• Others

Global Psychedelic Drugs Market Size by Route Of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Inhalation
• Injectable

Global Psychedelic Drugs Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Clinics
• Homecare
• Others

Global Psychedelic Drugs Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Global Psychedelic Drugs Market Size & CAGR (2026-2033)

• North America (Source, Type, Drug, Application, Route of Administration, End-User, Distribution Channel)
  • USA
  • Canada
• Europe (Source, Type, Drug, Application, Route of Administration, End-User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Source, Type, Drug, Application, Route of Administration, End-User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Source, Type, Drug, Application, Route of Administration, End-User, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Source, Type, Drug, Application, Route of Administration, End-User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jazz Pharmaceuticals (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Compass Pathways (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MindMed (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Atai Life Sciences (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cybin Corp. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Field Trip Health (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GH Research (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Beckley Psytech (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Seelos Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Numinus Wellness Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Delix Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mydecine Innovations Group (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Revive Therapeutics Ltd. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Entheon Biomedical (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mind Cure Health Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PsyBio Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tryp Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations